NTRA · Natera, Inc. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $390.42 to $390.63 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
220 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $389.3650 to $390.2850 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
2,320 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $389.3650 to $390.2050 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
1,935 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $388.35 to $389.33 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
1,341 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $387.21 to $388.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
2,846 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $387.21 to $388.12 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
2,734 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $386.1750 to $387.1700 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
2,175 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $388.3050 to $389.0400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
1,293 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $386.17 to $387.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
2,300 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.0350 to $386.0150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
390 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
110 |
| 2026-09-23 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.0350 to $385.1900 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
400 |
| 2026-09-16 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. |
Common Stock
|
200 |
| 2026-09-16 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.7150 to $357.0600 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
200 |
| 2026-09-16 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.2700 to $354.2450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,400 |
| 2026-09-16 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. |
Common Stock
|
100 |
| 2026-09-16 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.7350 to $356.6550 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
800 |
| 2026-09-16 | Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
Gift↓
Filing footnotes — Common Stock (Direct)
Represents a charitable contribution by the Reporting Person. |
Common Stock
|
945 |
| 2026-09-16 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.54 to $355.44 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
450 |
| 2026-09-15 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.1750 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
6,000 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.95 to $342.91 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,956 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $343.00 to $343.97 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
2,240 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $346.10 to $347.07 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,122 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $347.12 to $348.09 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
2,700 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.12 to $349.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
8,094 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.00 to $344.99 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
5,839 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $338.82 to $339.75 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,481 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.89 to $341.87 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,813 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.07 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
(I)
|
2,000 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.20 to $351.27 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
800 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.15 to $350.14 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
4,206 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $345.00 to $345.96 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
2,700 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $339.82 to $340.78 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
2,549 |
| 2026-09-15 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.20 to $351.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
14,500 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.88 to $341.83 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
2,700 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.75 to $335.74 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
3,754 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.03 to $342.76 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
4,064 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $336.75 to $337.71 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
2,207 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.60 to $333.57 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
2,246 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $339.87 to $340.72 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
2,000 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.54 to $330.52 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
6,206 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.50 to $328.46 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,537 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.75 to $336.74 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
8,459 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.53 to $329.51 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
6,015 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $338.80 to $339.74 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
2,100 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.71 to $334.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
2,818 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $337.76 to $338.75 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,400 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.55 to $331.45 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
3,494 |
| 2026-09-14 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.58 to $332.52 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,000 |
| 2026-09-11 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $326.50 to $327.49 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
10,556 |